AABS Events

Special
Projects

Follow Us

 

 

Case Study: GLAXOSMITHKLINE AND AIDS DRUGS IN SOUTH AFRICA (A): THE FIGHT FOR LIVES AND PROFITS

Title
GLAXOSMITHKLINE AND AIDS DRUGS IN SOUTH AFRICA (A): THE FIGHT FOR LIVES AND PROFITS 

Author
Yaziji, M ; Lindblom, A 

Pages
10 

Product Type
 

Reference #
IMD-3-1496 

Teaching Note
 

Institute

Setting
 

Year
 

Keywords
Non-government organisations (NGO's) ; Non-market competition ; Ethics ; Pharmaceutical ; AIDS ; Patents; South Africa; Pharmaceutical; Largest pharmaceutical company in the world, more than 100,000 employees; 2001-2004



Summary/
Abstract
This is the first of a four-case series (IMD-3-1496 to IMD-3-1499). The case describes the interactions among pharmaceutical companies, non- government organisations (NGO's), and governments in the context of the AIDS epidemic in South Africa. Oxfam singled out GlaxoSmithKline (GSK) as the target for its new campaign, 'Cut the Cost'. The goal was to hit where it would hurt the most - GSK's share price. At the same time other NGO's also went after GSK. For GSK the situation in South Africa was extremely delicate. The ultimate issues were patent and price protection globally. The pharmaceutical companies were afraid that cheap generic drugs could flood the West, undermining the entire pricing structure and their ability to fund new research. Defending the patents and prices seemed essential. Yet, fighting the NGO's could bring negative publicity and, ultimately, be self-defeating. Meanwhile, millions of people were dying of AIDS in South Africa.

 


 

 

 

AABS Insight Newsletter

AABS Insight is the Association's quarterly newsletter.

Sign Up Here

 

Emerald/AABS Case Study Competition

Apply for the 2015 Emerald/AABS Case Study Competition

Sign Up Here

 

AABS Case Studies

Over 300 African case studies are listed in the AABS case study database.

Submit a Case Study Here

View a Case Study Here